Articles

  • 5 days ago | fredhutch.org | Sabrina Richards

    Infectious disease specialist Camille Kotton, MD, clinical director of Massachusetts General Hospital’s Transplant Infectious Disease and Immunocompromised Host Program, discussed novel vaccines and monoclonal antibodies for respiratory viruses, including respiratory syncytial virus, or RSV. This virus causes a lot of disease in immunocompromised people, but those younger than 60 are not currently included in the Center for Disease Control’s RSV vaccination guidelines.

  • 1 month ago | fredhutch.org | Sabrina Richards

    After receiving his PhD in biostatistics at the University of Washington, Gilbert moved to Zelen’s department at Harvard, focusing on analyzing and designing clinical trials to test treatments for HIV. From the beginning, he integrated students into his research, a theme that would continue throughout his career. In 2001, Gilbert’s doctoral mentor, UW biostatistician Steven Self, PhD, enticed him back to Seattle to support the rapidly expanding statistical science developments at Fred Hutch.

  • 2 months ago | fredhutch.org | Sabrina Richards

    Bradley and Abdel-Wahab have a long-standing collaboration working out how mutations in certain splicing factor genes drive leukemia, with an eye toward leveraging the knowledge to develop new treatments. “We were wondering, could cancers with mutations in the splicing machineries just on their own generate novel proteins that could be really amazing therapeutic targets — if we could figure out what those novel proteins are and what the immune cells that recognize them are,” Abdel-Wahab said.

  • Mar 20, 2025 | fredhutch.org | Sabrina Richards

    Jerome’s lab, in the Vaccine and Infectious Disease Division at Fred Hutch, focuses on viruses that persist in their hosts and evade the immune system. While viruses like influenza come and go, others can set up permanent homes in our cells. Viruses like herpes simplex virus (HSV), hepatitis B, HIV and (occasionally) human papillomavirus, have found different ways to stick with us.

  • Feb 16, 2025 | jons-online.com | Sabrina Richards

    Brand-new cancer drugs typically take about 10 to 20 years to develop. And that’s just too long, as far as Fred Hutchinson Cancer Center’s Taran Gujral, PhD, is concerned — especially when it comes to rare cancers that are less likely to get attention from the pharmaceutical industry.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →